Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The receptor activator of NF-kappaB (RANK) belongs to the neuregulin/tumor necrosis factor (TNF) receptor superfamily and is activated by RANK ligand (RANK-L), a homotrimeric, TNF-like cytokine. RANK is present on the surface of osteoclast cell precursors, where its interaction with RANK-L induces their terminal differentiation into osteoclasts, thus increasing bone breakdown. The secreted, soluble receptor osteoprotegerin (OPG) interrupts this activation by binding directly to RANK-L. Therefore, osteoclast maturation (and bone homeostasis) is regulated in vivo by OPG levels of expression. We have studied the assembly state and affinity of OPG for RANK-L by sedimentation analyses and surface plasmon resonance (Biacore). Full-length, homodimeric OPG binds to RANK-L with a KD of 10 nM. OPG is also a member of the TNF receptor superfamily and contains four disulfide-rich ligand-binding domains, yet lacks a transmembrane region separating the ligand-binding region from the two death domains, as observed for other receptor family members. We showed that dimerization of OPG results from noncovalent interactions mediated by the death domains and to a lesser extent by a C-terminal heparin-binding region. In contrast, a C-terminal intermolecular disulfide bond does not contribute to the formation or stability of OPG dimers. A truncate of osteoprotegerin, containing the ligand-binding domains but lacking the dimerization domains, bound RANK-L with a KD of approximately 3 microM, indicating that monomer oligomerization for the OPG provides an increase of 3 orders of magnitude in the affinity for RANK-L. Therefore, OPG dimer formation is required for the mechanism of inhibition of the RANK-L/RANK receptor interaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ability of OPG to suppress bone resorption and increase bone mass is related to its ability to bind via its TNF receptor domains to TNF domains within its natural ligand (17), now known as RANKL.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
In the citing paper
“to its target RANKL (17) and for osteoclast inhibition in cell culture studies (4,16).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
In the citing paper
“However, more recent analyses using analytical ultracentrifugation to more accurately identify monomer vs. homodimer forms revealed that the OPG homodimer had 1000-fold greater affinity for RANKL than the monomeric form (17).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling
Guex, N., & Peitsch, M. C. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150181505 · Cited by 11,241
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Enhanced genome annotation using structural profiles in the program 3D-PSSM 1 1Edited by J. Thornton
Kelley, L. A., MacCallum, R. M., & Sternberg, M. J. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3741 · Cited by 1,468
TNF? and the TNF receptor superfamily: Structure-function relationship(s)
Idriss, H. T., & Naismith, J. H. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<184::aid-jemt2>3.0.co;2-h · Cited by 1,183
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173
Research works printed but not linked: 2
- South-Paul, 2001, Am. Family Physician, 63, 897
- Carolino, 1998, Am. Family Physician, 57, 1293
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Multiple Genetic Loci for Bone Mineral Density and Fractures
Styrkarsdottir, U., Halldorsson, B. V., Gretarsdottir, S., Gudbjartsson, D. F., Walters, G. B., Ingvarsson, T., Jonsdottir, T., Saemundsdottir, J., Center, J. R., Nguyen, T. V., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801197 · Cited by 629
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
Baud’huin, M., Lamoureux, F., Duplomb, L., Rédini, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 170
Osteoprotegerin: Multiple partners for multiple functions
Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.001 · Cited by 153
“However, it has been shown that the OPG homodimer exhibits higher affinity for the RANKL homotrimer [6,25].”
BackgroundThe Role of Osteoprotegerin and Its Ligands in Vascular Function
Rochette, L., Méloux, A., Rigal, E., Zeller, M., Cottin, Y., & Vergely, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030705 · Cited by 156
Structural and Functional Insights of RANKL–RANK Interaction and Signaling
Liu, C., Walter, T. S., Huang, P., Zhang, S., Zhu, X., Wu, Y., Wedderburn, L. R., Tang, P., Owens, R. J., Stuart, D. I., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904033 · Cited by 136
“one RANKL trimer by occupying two of the three binding sites on the ligand (60).”
BackgroundRANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor
Nelson, C. A., Warren, J. T., Wang, M. W.-H., Teitelbaum, S. L., & Fremont, D. H. (2012) · Structure · doi:10.1016/j.str.2012.08.030 · Cited by 132
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Zauli, G., Corallini, F., Bossi, F., Fabio Fischetti, I., Durigutto, P., Celeghini, C., Tedesco, F., & Secchiero, P. (2007) · Blood · doi:10.1182/blood-2007-01-068395 · Cited by 138
“OPG dimer formation is required for the mechanism of inhibition of the RANKL/RANK receptor interaction.(3) OPG can also interact with another member of the TNF superfamily, TNF-related apoptosis inducing ligand (TRAIL),(4) which shows the ability to kill a variety of cancer cell types both in vivo and in vitro.”
BackgroundVitovski, S., Phillips, J. S., Sayers, J. R., & Croucher, P. I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706078200 · Cited by 153
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
Castellano, D., Sepúlveda-Sánchez, J. M., García-Escobar, I., Rodríguez-Antolín, A., Sundlöv, A., & Cortés-Funes, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0154 · Cited by 138
Pathophysiological roles of osteoprotegerin (OPG)
Reid, P., & Holen, I. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.06.004 · Cited by 143
Fukada, S. Y., Silva, T. A., Garlet, G. P., Rosa, A. L., Silva, J. S., & Cunha, F. Q. (2008) · Oral Microbiology and Immunology · doi:10.1111/j.1399-302x.2008.00469.x · Cited by 129
“resorption around the tooth apex involves production of direct regulators of osteoclastic activity (RANKL and OPG) and osteoclastic chemotactic factors and receptors (5, 19, 35, 51).”
Survey of the year 2005 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2006) · Journal of Molecular Recognition · doi:10.1002/jmr.808 · Cited by 136
Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie, A., Takami, M., Kubo, H., Sekino-Suzuki, N., Kasahara, K., & Sanai, Y. (2007) · Bone · doi:10.1016/j.bone.2007.04.190 · Cited by 116
“The dimerization of OPG is mediated by the N-terminal domain of OPG, and induces the formation of OPG–RANKL complex [28].”
BackgroundMolecular mechanisms of inflammatory bone damage: emerging targets for therapy
Herman, S., Krönke, G., & Schett, G. A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.04.001 · Cited by 122
Rochette, L., Méloux, A., Rigal, E., Zeller, M., Cottin, Y., & Vergely, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.015 · Cited by 112
Crystal Structure of Human RANKL Complexed with Its Decoy Receptor Osteoprotegerin
Luan, X., Lu, Q., Jiang, Y., Zhang, S., Wang, Q., Yuan, H., Zhao, W., Wang, J., & Wang, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103387 · Cited by 112
“In contrast, the full-length OPG is a disulfide-bond linker dimer, and it was reported that trimeric RANKL interacts with dimeric OPG to mainly form a stable 1:1 trimer/dimer complex in solution (34).”
BackgroundInfluentialThéoleyre, S., Tat, S. K., Vusio, P., Blanchard, F., Gallagher, J. T., Ricard‐Blum, S., Fortun, Y., Padrines, M., Rédiní, F., & Heymann, D. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.120 · Cited by 107
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver
Musso, G., Paschetta, E., Gambino, R., Cassader, M., & Molinaro, F. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.006 · Cited by 102
Silva, T. A., Batista, A. C., Mendonça, E. F., Leles, C. R., Fukada, S. Y., & Cunha, F. Q. (2007) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2007.06.009 · Cited by 93
Emerging Functions of RANKL in Lymphoid Tissues
Mueller, C. G., & Hess, E. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00261 · Cited by 84
“The affinity of RANKL for OPG is 1000-fold higher than for RANK (Nakagawa et al., 1998), which is dependent on the ability of OPG to homodimerize (Schneeweis et al., 2005).”
BackgroundRole of RANKL in bone diseases
Anandarajah, A. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.10.007 · Cited by 84
The Endocannabinoid/Endovanilloid System in Bone: From Osteoporosis to Osteosarcoma
Rossi, F., Tortora, C., Punzo, F., Bellini, G., Argenziano, M., Paola, A. D., Torella, M., & Perrotta, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081919 · Cited by 78
“Osteoblasts also release osteoprotegrin (OPG), a soluble glycoprotein that acts as a “decoy” receptor binding to RANK-L and thus inhibiting osteoclast activation [4].”
van Dam, P. A., Verhoeven, Y., Trinh, X. B., Wouters, A., Lardon, F., Prenen, H., Smits, E., Baldewijns, M. M. L. L., & Lammens, M. M. Y. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.011 · Cited by 76
Role of full-length osteoprotegerin in tumor cell biology
Zauli, G., Melloni, E., Capitani, S., & Secchiero, P. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8536-x · Cited by 79
Genetics and aetiology of Pagetic disorders of bone
Helfrich, M., & Hocking, L. J. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.02.045 · Cited by 76
Microarray and Proteomic Analysis of Breast Cancer Cell and Osteoblast Co-cultures
Morrison, C., Mancini, S., Cipollone, J., Kappelhoff, R., Roskelley, C. D., & Overall, C. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.222513 · Cited by 67
The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies
Wallach, D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028431 · Cited by 66
“Cite this article as Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a028431 The self-association of four of the receptors (CD40, NGFR, CD27, and the soluble receptor OPG) is facilitated by constitutive cysteine links (found in the ID of CD40, in the TDofNGFR, at the carboxyl terminus of OPG, and apparently in…”
BackgroundInfluentialRochette, L., Méloux, A., Rigal, E., Zeller, M., Malka, G., Cottin, Y., & Vergely, C. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00573-6 · Cited by 74
Role of the RANK/RANKL pathway in breast cancer
Kiesel, L., & Kohl, A. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.01.001 · Cited by 64
Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells
Lang, I., Füllsack, S., Wyzgol, A., Fick, A., Trebing, J., Arana, J. A. C., Schäfer, V., Weisenberger, D., & Wajant, H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.683946 · Cited by 65
Ramos, Y. F., Bos, S. D., van der Breggen, R., Kloppenburg, M., Ye, K., Lameijer, E.-W., Nelissen, R. G. H. H., Slagboom, P. E., & Meulenbelt, I. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205149 · Cited by 61
Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma
Lamoureux, F., Picarda, G., Garrigue-Antar, L., Baud'huin, M., Trichet, V., Vidal, A., Miot-Noirault, E., Pitard, B., Heymann, D., & Rédini, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2648 · Cited by 55
“To get further insight into the regulation of OPG bioactivity in bone tumors, in vivo experiments were performed comparing the biological activity of two forms of OPG [OPG full length (1-401) and OPG (1-194) lacking its heparin-binding domain, the two death domains, and the C-400 responsible for OPG dimerization] admi…”
BackgroundMethodInfluentialFunction of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis
Aoki, S., Honma, M., Kariya, Y., Nakamichi, Y., Ninomiya, T., Takahashi, N., Udagawa, N., & Suzuki, H. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.89 · Cited by 51
TSG-6 Regulates Bone Remodeling through Inhibition of Osteoblastogenesis and Osteoclast Activation
Mahoney, D. J., Mikecz, K., Ali, T., Mabilleau, G., Benayahu, D., Plaas, A., Milner, C. M., Day, A. J., & Sabokbar, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802138200 · Cited by 54
Nakamichi, Y., Udagawa, N., Kobayashi, Y., Nakamura, M., Yamamoto, Y., Yamashita, T., Mizoguchi, T., Sato, M., Mogi, M., Penninger, J. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.192 · Cited by 50
“It was reported that OPG exists and acts as a homodimeric form (35).”
BackgroundAkiyama, T., Miyamoto, Y., Yoshimura, K., Yamada, A., Takami, M., Suzawa, T., Hoshino, M., Imamura, T., Akiyama, C., Yasuhara, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.520510 · Cited by 50
Kondo, T., Kanayama, K., Egusa, H., & Nishimura, I. (2022) · Journal of Prosthodontic Research · doi:10.2186/jpr.jpr_d_21_00333 · Cited by 57
Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment
Lamoureux, F., Moriceau, G., Picarda, G. G. A., Rousseau, J., Trichet, V., & Rédiní, F. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.004 · Cited by 49
Osteoprotegerin and kidney disease
Montanez-Barragan, A., Gómez-Barrera, I., Sánchez-Niño, M. D., Ucero, A. C., González–Espinoza, L., & Ortíz, A. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0092-x · Cited by 42
“OPG-Fc lacks the signal-peptide, heparin-binding domain and death domain-homologous regions of native OPG, has a longer half-life and lower affinity for TRAIL, while affinity for RANKL is preserved [22, 61].”
BackgroundInfluentialBaek, J. M., Kim, J., Yoon, K., Oh, J., & Lee, M. S. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.13815 · Cited by 47
“OPG, a member of the TNF receptor family, plays a role as a competitive receptor antagonist by binding and neutralizing RANKL, thus inhibiting the differentiation and fusion of osteoclast precursors and the function of mature osteoclasts [28, 29].”
BackgroundHeparan Sulfate Regulates the Structure and Function of Osteoprotegerin in Osteoclastogenesis
Li, M., Yang, S., & Xu, D. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.751974 · Cited by 48
“Although an earlier study suggests that the dimer is mediated by an intermolecular disulfide bond formed at Cys(400) (7), a recent study challenges this view (8).”
BackgroundResultInfluentialHeparin-regulated delivery of osteoprotegerin promotes vascularization of implanted hydrogels
McGonigle, J. S., Tae, G., Stayton, P. S., Hoffman, A. S., & Scatena, M. (2008) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856208784909381 · Cited by 43
Dickkopf-1 as Potential Biomarker to Evaluate Bone Erosion in Systemic Lupus Erythematosus
Long, L., Liu, Y., Wang, S., Zhao, Y., Guo, J., Yu, P., & Li, Z. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9436-z · Cited by 35
“Osteoprotegerin (OPG) is the soluble decoy receptor of receptor activator, nuclear factor-κB ligand (RANKL), which can block osteoclast differentiation and, thus, protect against bone destruction [9].”
BackgroundNormal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro
Chakravarti, A., Marceau, A.-A., Flamand, L., & Poubelle, P. E. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700701 · Cited by 37
Kaneuji, T., Ariyoshi, W., Okinaga, T., Toshinaga, A., Takahashi, T., & Nishihara, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.128 · Cited by 36
RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review
van Dam, P. A., Verhoeven, Y., Jacobs, J., Wouters, A., Tjalma, W. A. A., Lardon, F., WYNGAERT, T. V. D., Dewulf, J., Smits, E., Colpaert, C., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092183 · Cited by 34
“The dimerization of OPG increases the affinity of OPG to RANKL dramatically [20].”
BackgroundOsteoprotegerin Enhances Osteogenesis of Human Mesenchymal Stem Cells
Palumbo, S. L., & Li, W. (2013) · Tissue Engineering Part A · doi:10.1089/ten.tea.2012.0550 · Cited by 29
“Previous studies have reported that OPG suppresses NF-k B activation in osteoclast precursors through the binding of its ligand RANKL.”
InfluentialSugisaki, R., Miyamoto, Y., Yoshimura, K., Sasa, K., Kaneko, K. J., Tanaka, M., Itose, M., Inoue, S., Baba, K., Shirota, T., et al. (2019) · Bone · doi:10.1016/j.bone.2019.115216 · Cited by 27
Payr, S., Balmayor, E. R., Tiefenboeck, T. M., Schuseil, T., Unger, M., Seeliger, C., & van Griensven, M. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-02153-z · Cited by 26
“These osteoblastic markers indicate osteoblast’s activity and represent bone formation, except for OPG, which is a glycoprotein produced by osteoblasts suppressing bone resorption and increases bone mass [8].”
BackgroundPropofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts
Lee, D.-W., Kwon, J.-Y., Kim, H.-K., Lee, H. J., Kim, E., Kim, H. J., Kim, H. J., & Lee, H.-B. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.22713 · Cited by 26
Markers of bone remodeling in neoplastic and bone-related lesions
Elias, L. S. A., Costa, R., de Carvalho, M. A., Batista, A. C., Silva, T. A., Leles, C. R., & Mendonça, E. F. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2010.06.014 · Cited by 31
Bowsher, R. R., & Sailstad, J. M. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.09.026 · Cited by 27
Brito-Mendoza, L., Bologna‐Molina, R. E., Irigoyen‐Camacho, M. E., Martinez, G., Sánchez‐Romero, C., & Mosqueda‐Taylor, A. (2018) · Disease Markers · doi:10.1155/2018/7048531 · Cited by 23
“Osteoprotegerin (OPG) is a soluble receptor that disrupts osteoclast activation by binding directly to RANK; therefore, osteoclast maturity and bone homeostasis are given by balanced RANKRANKL and OPG levels [4, 5].”
BackgroundArthur, K. K., Gabrielson, J. P., Hawkins, N., Anafi, D., Wypych, J., Nagi, A., Sullivan, J. K., & Bondarenko, P. V. (2012) · Biochemistry · doi:10.1021/bi2007806 · Cited by 23
RANK, RANKL and OPG Expression in Breast Cancer – Influence on Osseous Metastasis
Ney, J. T., Fehm, T. N., Juhasz-Böess, I., & Solomayer, E. (2012) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0031-1298276 · Cited by 26
Are OPG and RANKL involved in human fracture healing?
Starlinger, J., Thomas, A., Gregori, M., Kecht, M., Kaiser, G., Eipeldauer, S., & Sarahrudi, K. (2014) · Journal of Orthopaedic Research® · doi:10.1002/jor.22723 · Cited by 26
“Thereby, OPG suppresses bone resorption and increases bone mass.(7) Thus, the OPG/RANKL ratio reflects the rate of bone resorption in general and its role is well recognized in osteoporosis.”
BackgroundUnraveling Binding Interactions between Human RANKL and Its Decoy Receptor Osteoprotegerin
Munasinghe, A., Lin, P. C., & Colina, C. M. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b06687 · Cited by 22
Dündar, Ü., Kavuncu, V., Çiftçi, İ. H., Evcik, D., Solak, Ö., & Çakır, T. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0055-9 · Cited by 23
Characterisation of Osteoprotegerin Autoantibodies in Coeliac Disease
Real, A., Gilbert, N., Hauser, B., Kennedy, N. A., Shand, A. G., Gillett, H. R., Gillett, P. M., Goddard, C., Cebolla, Á., Sousa, C., et al. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0023-4 · Cited by 19
“The recombinant plasmids pETOPG1 and pET-OPG2 express the amino-terminal cysteine-rich domains (D1–D4) which are necessary for binding to RANKL [15, 16].”
BackgroundMorony, S., Dwyer, D., Stolina, M., Kostenuik, P. J., Tintut, Y., Zhang, Z., Demer, L. L., Cattley, R. C., & Van, G. Y. (2008) · Circulation · doi:10.1161/circulationaha.108.782649 · Cited by 18
Zavaczki, E., Gáll, T., Zarjou, A., Hendrik, Z., Potor, L., Tóth, C. Z., Méhes, G., Gyetvai, Á., Agarwal, A., Balla, G., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3721383 · Cited by 18
“As a dimer, OPG competes with RANK for RANKL binding and e ff ectively inhibits RANK-RANKL interaction [62].”
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
Anastasilakis, A. D., Yavropoulou, M. P., Palermo, A., Makras, P., Paccou, J., Tabacco, G., Naciu, A. M., & Tsourdi, E. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae076 · Cited by 17
Makihira, S., Nikawa, H., Shuto, T., Nishimura, M., Mine, Y., Tsuji, K., Okamoto, K., Sakai, Y., Sakai, M., Imari, N., et al. (2011) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-011-4440-2 · Cited by 17
“These reports suggest that the conformation and/or activity of the molecule after the immobilization process are very important for the function of the immobilized protein [3, 21, 33–35].”
BackgroundMakihira, S., Mine, Y., Nikawa, H., Shuto, T., Kosaka, E., Sugiyama, M., & Hosokawa, R. (2009) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-009-3891-1 · Cited by 18
“The inhibitory effects of OPG-Fc immobilized on titanium surfaces against the actions of sRANKL were active within 2 days in the presence of FBS (Fig. 4). In addition, it is reported that OPG dimer formation is required for the inhibition of the RANKL/RANK receptor interaction [ 32 ].”
BackgroundSoory, M. (2010) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s10928 · Cited by 27
Lee, E., Na, W., Kang, M., Kim, Y., Kim, D., Oh, H., Kim, S., Oh, S.-Y., Park, S., Park, K., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9060648 · Cited by 15
“OPG that is produced by osteoblasts binds to RANKL as a soluble decoy receptor, which leads to the inhibition of osteoclast differentiation and subsequent bone resorption [31,32].”
BackgroundOsteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives
Jayash, S. N., Al-Namnam, N. M., & Shaghayegh, G. (2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac102.193200 · Cited by 17
“But in another study, dimeric form of OPG is a more potent RANKL inhibitor than the monomeric form, this study was reported in Schneeweis and co-workers [9].”
ResultProtein Assembly in Serum and the Differences from Assembly in Buffer
Hill, J. J., & Laue, T. M. (2015) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2015.06.012 · Cited by 12
Liu, H., Ru, N., Cai, Y., Lyu, Q., Guo, C.-H., Zhou, Y., Li, S., Cheng, J., Chang, J.-R., Ma, J., et al. (2021) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0329 · Cited by 11
Clinical and basic research papers – November 2005 selections
Ferrari, S., Seeman, E., & Strewler, G. J. (2005) · BoneKEy-Osteovision · doi:10.1138/20050186 · Cited by 11
Boroń, D., Kotrych, D., Bartkowiak-Wieczorek, J., Uzar, I., Bogacz, A., & Kamiński, A. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.07.015 · Cited by 11
The pathogenesis of osteoclast diseases: Some knowns, but still many unknowns
Helfrich, M., Crockett, J. C., Hocking, L. J., & Coxon, F. P. (2007) · BoneKEy-Osteovision · doi:10.1138/20060249 · Cited by 11
“OPG in its homodimeric form binds with much higher affinity to RANKL than the OPG monomer (37) and has previously been shown to have higher in vivo potency for inhibiting bone resorption (38).”
BackgroundWarren, J. T., Nelson, C. A., Decker, C. E., Zou, W., Fremont, D. H., & Teitelbaum, S. L. (2014) · Science Signaling · doi:10.1126/scisignal.2004948 · Cited by 10
Role of Sandhika: A Polyherbal Formulation on MC3T3-E1 Osteoblast-like Cells
Tripathi, Y. B., Tripathi, P., Korlagunta, K., Chai, S. C., Smith, B. J., & Arjmandi, B. H. (2007) · Inflammation · doi:10.1007/s10753-007-9044-0 · Cited by 10
“Therefore, the inhibitory effect of any agent on p21(ras)-dependent NF-kappaB activation, p38 MAPK mediated release of IL-6 and PGE-2 production may have potential therapeutic value for arthritis and other inflammatory diseases [23].”
BackgroundRANK/RANKL Signaling Pathway in Breast Development and Cancer
Pérez-Chacón, G., Santamaría, P. G., Redondo-Pedraza, J., & González‐Suárez, E. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_16 · Cited by 10
Beyond bone remodeling–emerging functions of osteoprotegerin in host defense and microbial infection
Kobayashi‐Sakamoto, M., Tamai, R., & Kiyoura, Y. (2015) · Integrative Molecular Medicine · doi:10.15761/imm.1000173 · Cited by 10
“The affinity of the OPG dimer for RANKL is much higher than that of the monomeric form [6].”
BackgroundCathepsin K degrades osteoprotegerin to promote osteoclastogenesis in vitro
Kawai, R., Sugisaki, R., Miyamoto, Y., Yano, F., Sasa, K., Minami, E., Maki, K., & Kamijo, R. (2023) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-023-00747-5 · Cited by 8
“OPG forms a homodimer with a disulfide bridge between the C-terminal cysteine residues and binds to the RANKL trimer (Schneeweis et al. 2005).”
Backgroundde Sousa, B. L., Barroso-Neto, I. L., Oliveira, E. F., Fonseca, E. A., de Lima‐Neto, P., Ladeira, L. O., & Freire, V. N. (2016) · RSC Advances · doi:10.1039/c6ra16712h · Cited by 8
Osteoclast Differentiation and Function
Filgueira, L. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00005-0 · Cited by 11
Takahashi, N., Udagawa, N., Kobayashi, Y., Takami, M., Martin, T. J., & Suda, T. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00029-x · Cited by 18
Dimerization interface of osteoprotegerin revealed by hydrogen–deuterium exchange mass spectrometry
Xiao, Y., Li, M., Larocque, R., Zhang, F., Malhotra, A., Chen, J., Linhardt, R. J., Konermann, L., & Xu, D. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004489 · Cited by 7
The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer
van Dam, P. A., Verhoeven, Y., & Trinh, X. B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_3 · Cited by 7
Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta
Passaponti, S., Ermini, L., Acconci, G., Severi, F. M., Romagnoli, R., Cutrupi, S., Clerico, M., Guerrera, G., & Ietta, F. (2022) · Cells · doi:10.3390/cells11081357 · Cited by 7
“Intriguingly, we have found that the fetal organ produces predominantly the homodimeric form of the protein known to increase of three orders of magnitude its affinity for RANKL, therefore, inhibiting the RANKL–RANK receptor interaction more powerfully [47].”
BackgroundOsteoprotegerin and Inflammation in Incident Peritoneal Dialysis Patients
Małecki, M., Okulewicz, P., Lisak, M., Safranow, K., Domański, L., Ciechanowski, K., & Gołembiewska, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082345 · Cited by 6
Denosumab for treatment of breast cancer bone metastases and beyond
Nangia, J. R., JOSEPH, D. R., Nguyen, C. M., Mendes, M., & Trivedi, M. V. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.664634 · Cited by 7
“Osteoclast activity is counterbalanced, in part, by osteoblast production of OPG, in which OPG binds to RANKL [55].”
BackgroundRANK pathway in cancer: underlying resistance and therapeutic approaches
Tufail, M., & Wu, C. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2129752 · Cited by 5
“To decrease RANK/RANKL, OPG must be dimerized, which greatly increases OPG’s affinity for RANKL (Figure 1) [26].”
Secchiero, P., & Zauli, G. (2008) · Circulation · doi:10.1161/circulationaha.108.765776 · Cited by 5
Metabolic Disorders in Patients with Chronic Osteomyelitis: Etiology and Pathogenesis
Важаевич, Ц. А., Zagorodny, N. V., Rodionova, S. S., & Сергеевич, Г. Д. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92052 · Cited by 4
Suh, S. H., Oh, T. R., Choi, H. S., Kim, C. S., Bae, E. H., Kwon, S., Oh, K., Jung, J. Y., Hyun, Y. Y., Kim, S. W., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02382-w · Cited by 4
Effects of Epigallocatechin-3-O-Gallate on Bone Health
Wróbel, P., Czarczyńska-Goślińska, B., Chornovolenko, K., Liwarska, J., Kubiak, J., Koczorowski, T., Malińska, A., Gośliński, T. A., & Waszyk-Nowaczyk, M. (2025) · Applied Sciences · doi:10.3390/app15158182 · Cited by 3
Bone Development in Children and Adolescents
Boyanov, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-32122-6_6 · Cited by 7
Transglutaminase-2 Is Involved in Expression of Osteoprotegerin in MG-63 Osteosarcoma Cells
Lee, H. J., & Lee, C. (2013) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2013.037 · Cited by 3
“Furthermore, full-length OPG possesses RANKL-and TRAIL-independent biological properties, mainly related to the promotion of endothelial cell survival as well as angiogenesis and metastasis of breast cancer, ameloblastomas, and multiple myeloma (Holen et al., 2002; Shipman and Croucher, 2003; Zauli et al., 2009).”
BackgroundAn In Silico Model for the Prediction of Changes in Mineral Density in Cortical Bone Remodeling
Mattazio, R. R., Noritomi, P. Y., & Silveira, Z. D. C. (2019) · Journal of Biomechanical Engineering · doi:10.1115/1.4044094 · Cited by 3
Tariq, S., Jabbar, S., Ahmad, A., & Tariq, S. (2024) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.7.9072 · Cited by 4
“37 OPG is also identified as proinflammatory molecule and is associated with angiogenesis and vasculogenesis and is also involved in tumour metastasis and growth.”
Hirata, W., Itatani, Y., Masui, H., Kawada, K., Mizuno, R., Yamamoto, T. S., Okamoto, T., Ogawa, R., Inamoto, S., Maekawa, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-49312-w · Cited by 2
Buccarello, A. L., de Souza, A. L. S., Ullmann, M., & Petit-Frère, C. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2607080 · Cited by 1
Shibata, Y., Nishida‐Fukuda, H., Nakayama, H., Izumi, Y., Suzuki, R., Yokawa, S., Sato, T., Furuno, T., Matsubara, M., Miyazawa, K., et al. (2026) · Journal of Oral Biosciences · doi:10.1016/j.job.2025.100727 · Cited by 1
TNFRSF11B (tumor necrosis factor receptor superfamily, member 11b)
Di, I. M., Corallini, F., Secchiero, P., & Capitani, S. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/44519 · Cited by 1
“OPG consists of 7 structural domains, of which the aminoterminal cysteine rich domains 1 to 4 (D1-D4) are necessary for binding to RANKL (Schneeweis et al., 2005) and share some features with the extracellular domains of other members of the TNF-receptor family (Diagram 2) (Baker et al.”
Background
Metadata
- Authors
- Schneeweis, L. A., Willard, D., & Milla, M. E.
- Affiliations
- University of Pennsylvania (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Schneeweis, Lumelle A.
- Milla, Marcos E.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 280
- Issue
- 50
- Pages
- 41155-41164
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2000736649
- Cited by
- 116
- References
- 35
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 3 · 2016: 6 · 2015: 5 · 2014: 8 · 2013: 8 · 2012: 7
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5418 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r21dk067831-01)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK067831)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- osteoprotegerin, RANK ligand, RANK, TNF receptor superfamily, receptor dimerization, ligand binding affinity, death domain, disulfide bonds, osteoclastogenesis, bone homeostasis
- MeSH terms
- Animals, Antibody Affinity, Biological Assay, Carrier Proteins, Cell Differentiation, Cell Membrane, Circular Dichroism, Disulfides, Escherichia coli, Genetic Vectors, Glycoproteins, Heparin, Humans, Insecta, Kinetics, Ligands, Membrane Glycoproteins, Models, Chemical, Mutation, Osteoclasts, Protein Binding, Proteins, Time Factors, Viruses, Cytokines, Protein Structure, Tertiary, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Dimerization, Surface Plasmon Resonance, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.